Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers
NCT04213196Phase 1Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Sep 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hsk21542 in pain and pruritus (9 arms), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoints: Adverse Events / Serious Adverse Events at 3 weeks, Systolic and Diastolic Blood Pressure at 3 weeks and 2 more. Started Jan 2020; status: completed.
02
Drugs
hsk21542
03
Conditions
painpruritus
Beyond the preview
Go deeper on NCT04213196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213196.